Autobahn Therapeutics Email Formats

About Autobahn Therapeutics

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve. CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people. We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop novel, small molecule therapies that harness the regenerative power of the human body, with an initial focus on high unmet need areas neuropsychiatry, neurodegeneration, and neuroinflammation. Our pipeline is led by ABX-002, a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Want to join our team? Please see our open positions on the Careers page of the Autobahn website: https://autobahntx.com/careers/

View contact profiles from Autobahn Therapeutics